Corrección de la anemia en hemodiálisis, efecto del fierro intravenoso sin eritropoyetina
Background: In the last two decades, the use of erythropoietin for the correction of anemia in hemodialysis patients has been recommended. In Chile, only 10% of hemodialysis patients use erythropoietin, therefore, the correction of iron deficiency must be optimized. Aim: To report the effects of int...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Lenguaje: | Spanish / Castilian |
| Publicado: |
Sociedad Médica de Santiago
2002
|
| Materias: | |
| Acceso en línea: | http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872002000800004 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Background: In the last two decades, the use of erythropoietin for the correction of anemia in hemodialysis patients has been recommended. In Chile, only 10% of hemodialysis patients use erythropoietin, therefore, the correction of iron deficiency must be optimized. Aim: To report the effects of intravenous iron without erythropoietin in the management of anemia in hemodialysis patients. Material and methods: Retrospective analysis of 42 patients that received intravenous ferrous sacarate in doses of 100 mg/week during 5 weeks and 100 mg bimonthly during six months. These patients did not receive erythropoietin. Results. Thirty six patients had iron deficiency. Basal ferritin was 137±22 µg/l and increased to 321±28 µg/l after treatment. Packed red cell volume increased from 24±2% to 29±3%. No adverse effects were reported. Conclusions: Iron deficiency is frequent in hemodialyzed patients. Intravenous iron is safe and effective in the treatment of iron deficiency in these patients (Rev Méd Chile 2002; 130: 865-8) |
|---|